# mifepristone

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/mifepristone
Canonical HTML page: https://gethealthbrief.com/entity/mifepristone

## Timeline

- **2026-03-14**: Bill Signed into Law — Governor Inslee signs the measure, enabling the Department of Corrections to begin distribution to providers.
- **2026-03-13**: DOJ Missouri Filing — DOJ quietly asks the Missouri court to pause proceedings pending FDA review.
- **2026-03-11**: Legislative Action — Sen. Josh Hawley introduces a Senate bill to outright ban the abortion pill.
- **2026-01-20**: Louisiana Precedent — DOJ unsuccessfully asks Louisiana to pause its separate anti-abortion lawsuit.
- **2026-01-12**: Legislation Introduced — State lawmakers introduce a bill to clarify the state's authority to distribute the stockpile to clinics.
- **2025-11-15**: Amended Complaint — AG Catherine Hanaway adds claims that mail-order drugs are dangerous without in-person visits.
- **2025-10-01**: Lawsuit Filed — Missouri, Kansas, and Idaho file suit against the FDA over mifepristone regulations.
- **2024-06**: Supreme Court Ruling — SCOTUS maintains access to mifepristone by dismissing a challenge to FDA's rules on procedural grounds.
- **2023-05-15**: Inventory Secured — The Washington Department of Corrections receives and stores the medication supply.
- **2023-04-04**: Stockpile Ordered — Governor Inslee directs the purchase of 30,000 doses of mifepristone following a Texas court ruling.
- **2023-01**: Pharmacy Certification — FDA updates REMS to allow retail pharmacies to dispense mifepristone upon certification.
- **2021-12**: Mail-Order Authorization — FDA permanently removes the requirement for in-person dispensing, allowing for telehealth and mail delivery.
- **2016-03**: Protocol Expansion — FDA extends usage window to 10 weeks and reduces required office visits from three to one.
- **2000-09**: Initial FDA Approval — FDA approves mifepristone for medical termination of pregnancy through seven weeks.

## Recent coverage (4 stories)

### Medication Abortion Becomes Primary Method Amid Escalating Regulatory Warfare
2026-03-24 07:42:54 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Medication abortion now accounts for the majority of pregnancy terminations in the United States, driven by the expansion of telehealth and mail-order pharmacy access. This shift has sparked a sophisticated regulatory counter-offensive from opponents targeting FDA-approved protocols and cross-state digital health providers.
Full story: https://gethealthbrief.com/story/medication-abortion-regulation-trends-2026

### GOP Bill Proposes 'Catch Kits' and Telehealth Ban for Abortion Pills
2026-03-20 00:33:52 · Sentiment: Negative · Impact: 6/10 · Sources: 3

House Republicans have introduced the Clean Water For All Life Act, a novel regulatory attempt to classify abortion pill remains as environmental pollutants. The bill seeks to mandate 'catch kits' for patients, ban mail-order medication, and impose severe criminal penalties on providers and users.
Full story: https://gethealthbrief.com/story/gop-clean-water-act-abortion-telehealth-ban

### Washington Streamlines Distribution of State-Owned Abortion Pill Stockpile
2026-03-16 20:45:59 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Washington Governor Jay Inslee has signed legislation allowing the state to efficiently distribute its 30,000-dose stockpile of mifepristone to healthcare providers. The move solidifies the state's role as a direct supplier of reproductive healthcare in response to ongoing federal legal uncertainty.
Full story: https://gethealthbrief.com/story/washington-abortion-pill-stockpile-distribution-law

### DOJ Requests Pause in Missouri Mifepristone Lawsuit Citing Internal FDA Review
2026-03-13 00:34:35 · Sentiment: Negative · Impact: 8/10 · Sources: 2

The U.S. Department of Justice has requested a federal court in Missouri to pause or dismiss a lawsuit targeting the FDA's approval of mifepristone, citing an ongoing internal agency review. This move reflects a strategic effort by the administration to manage high-stakes litigation over medication abortion and telehealth access ahead of the 2026 midterms.
Full story: https://gethealthbrief.com/story/doj-missouri-mifepristone-lawsuit-pause

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.